Alzheimer’s pipeline featured on VRT NWS and Radio 1
Following the announcement of the first-in-human trial of our second-generation Alzheimer’s compound, the progress and potential of this investigational therapy were featured on VRT NWS and in De Ochtend on Radio 1 today.
10/7/25, 00:00
Following the announcement of the first-in-human trial of our second-generation Alzheimer’s compound, the progress and potential of this investigational therapy were featured on VRT NWS and in De Ochtend on Radio 1 today.
Our oral compound, currently being tested in healthy volunteers, is designed to address Alzheimer’s via a unique mechanism: restoring neuronal calcium balance and septin structure, both of which are disrupted in disease progression.
In the VRT segment, CSO Gerard Griffioen explains the science behind the compound, while CEO Floor Stam highlights its therapeutic vision and relevance for patient care.
Floor also discussed the study and broader Alzheimer’s context with Michael Van Droogenbroeck on De Ochtend (Radio 1). [Listen from 1:16:55]
“We believe that tackling Alzheimer’s will require a combination of therapies,” said Floor Stam. “This new oral compound is designed to fit into that future—easy to administer, biologically complementary, and focused on sustaining neuronal function.”
We thank our team, clinical partners, and stakeholders for their continued commitment. The study remains on track, and we look forward to sharing further updates as results emerge.